
## Anders Waage

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10932541/publications.pdf Version: 2024-02-01



ANDERS WAACE

#	Article	IF	CITATIONS
1	Thalidomide for treatment of multiple myeloma: 10 years later. Blood, 2008, 111, 3968-3977.	1.4	294
2	Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. Lancet Oncology, The, 2014, 15, 333-342.	10.7	256
3	Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. Blood, 2011, 118, 1239-1247.	1.4	243
4	Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood, 2002, 100, 3002-3007.	1.4	227
5	Glucocorticoids inhibit the production of IL 6 from monocytes, endothelial cells and fibroblasts. European Journal of Immunology, 1990, 20, 2439-2443.	2.9	217
6	Cytokine regulation of interleukin 6 production by human endothelial cells. Cellular Immunology, 1989, 121, 372-382.	3.0	161
7	Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood, 2001, 98, 2269-2271.	1.4	158
8	Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Blood, 2016, 127, 1109-1116.	1.4	102
9	High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity. Blood, 2000, 96, 3139-3146.	1.4	91
10	Regulation of interleukin-2 and interleukin-6 production from T-cells: Involvement of interleukin-1 β and transforming growth factor-β. Cellular Immunology, 1990, 126, 47-56.	3.0	82
11	Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials. Haematologica, 2013, 98, 87-94.	3.5	73
12	Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network. Leukemia, 2018, 32, 1542-1560.	7.2	68
13	Bone Disease in Multiple Myeloma. Medical Oncology, 2006, 23, 431-442.	2.5	14
14	Why do myeloma patients have bone disease? A historical perspective. Blood Reviews, 2020, 41, 100646.	5.7	13
15	Release of bioactive interleukin 6 but not of tumour necrosis factor-α after elective cardiopulmonary bypass. Perfusion (United Kingdom), 1993, 8, 233-238.	1.0	10
16	The Influence of Growth Hormone on Tumour Necrosis Factor and Neutrophil Leukocyte Function in Sepsis. Scandinavian Journal of Infectious Diseases, 1997, 29, 393-399.	1.5	8
17	Bmps(Bone Morphogenetic Proteins) Inhibit Growth in Multiple Myeloma Cells by p53 Activation Blood, 2004, 104, 3354-3354.	1.4	0